{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:04:51Z","timestamp":1791932691114,"version":"4.3.4"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81701814"],"award-info":[{"award-number":["81701814"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Materials Today Bio"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.mtbio.2022.100350","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T21:38:49Z","timestamp":1657143529000},"page":"100350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Improved anti-hepatocellular carcinoma effect by enhanced Co-delivery of Tim-3 siRNA and sorafenib via multiple pH triggered drug-eluting nanoparticles"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3746-9489","authenticated-orcid":false,"given":"Chenghua","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruichao","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Xiaoli liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongqian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mtbio.2022.100350_bib1","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1056\/NEJMcibr2106594","article-title":"Hepatocellular carcinoma - origins and outcomes","volume":"385","author":"Kelley","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.mtbio.2022.100350_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(21)02138-3","article-title":"Late presentation of hepatocellular carcinoma highlights the need for a public health programme to eliminate hepatitis B","volume":"398","author":"Nhlane","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.mtbio.2022.100350_bib3","article-title":"Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell-free DNA fragmentomics","author":"Zhang","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.mtbio.2022.100350_bib4","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/hep.31325","article-title":"Surgical treatments of hepatobiliary cancers","volume":"73","author":"Gunasekaran","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.mtbio.2022.100350_bib5","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.mtbio.2022.100350_bib6","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.mtbio.2022.100350_bib7","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.mtbio.2022.100350_bib8","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1007\/s10620-019-05582-x","article-title":"Systemic management for advanced hepatocellular carcinoma: a review of the molecular pathways of carcinogenesis, current and emerging therapies, and novel treatment strategies","volume":"64","author":"Saffo","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.mtbio.2022.100350_bib9","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/gutjnl-2018-316408","article-title":"Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial","volume":"68","author":"Pinyol","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.mtbio.2022.100350_bib10","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/annonc\/mdw054","article-title":"Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77\/08 and SASL 29)","volume":"27","author":"Koeberle","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.mtbio.2022.100350_bib11","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1021\/acs.biomac.5b01082","article-title":"Nanoassemblies based on supramolecular complexes of nonionic amphiphilic cyclodextrin and sorafenib as effective weapons to kill human HCC cells","volume":"16","author":"Bondi","year":"2015","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.mtbio.2022.100350_bib12","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1136\/gutjnl-2016-313547","article-title":"CDK4\/6 inhibition and sorafenib: a menage a deux in HCC therapy?","volume":"66","author":"Calvisi","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.mtbio.2022.100350_bib13","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jconrel.2021.01.021","article-title":"Ultra-small lipid nanoparticles encapsulating sorafenib and midkine-siRNA selectively-eradicate sorafenib-resistant hepatocellular carcinoma in vivo","volume":"331","author":"Younis","year":"2021","journal-title":"J.\u00a0Contr. Release"},{"key":"10.1016\/j.mtbio.2022.100350_bib14","doi-asserted-by":"crossref","first-page":"546","DOI":"10.21037\/hbsn.2019.04.14","article-title":"Is there a place for Ramucirumab after Sorafenib in patients with advanced HCC?","volume":"8","author":"So","year":"2019","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"10.1016\/j.mtbio.2022.100350_bib15","doi-asserted-by":"crossref","first-page":"20360","DOI":"10.1021\/acsami.5b06203","article-title":"Multilayer-coated liquid crystalline nanoparticles for effective sorafenib delivery to hepatocellular carcinoma","volume":"7","author":"Thapa","year":"2015","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.mtbio.2022.100350_bib16","doi-asserted-by":"crossref","first-page":"5464","DOI":"10.7150\/thno.54822","article-title":"Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma","volume":"11","author":"Kong","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.mtbio.2022.100350_bib17","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.ymthe.2021.03.009","article-title":"Liver gene therapy and hepatocellular carcinoma: a complex web","volume":"29","author":"de Jong","year":"2021","journal-title":"Mol. Ther. : the journal of the American Society of Gene Therapy"},{"key":"10.1016\/j.mtbio.2022.100350_bib18","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1038\/ncomms4869","article-title":"Nanoparticle-formulated siRNA targeting integrins inhibits hepatocellular carcinoma progression in mice","volume":"5","author":"Bogorad","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2022.100350_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abh4456","article-title":"An AAV gene therapy computes over multiple cellular inputs to enable precise targeting of multifocal hepatocellular carcinoma in mice","volume":"13","author":"Angelici","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.mtbio.2022.100350_bib20","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/hep.20613","article-title":"Combined endostatin\/sFlt-1 antiangiogenic gene therapy is highly effective in a rat model of HCC","volume":"41","author":"Graepler","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.mtbio.2022.100350_bib21","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1038\/s41467-018-05764-7","article-title":"Nanomedicines reveal how PBOV1 promotes hepatocellular carcinoma for effective gene therapy","volume":"9","author":"Guo","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2022.100350_bib22","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jconrel.2020.11.020","article-title":"Targeted delivery of siRNAs against hepatocellular carcinoma-related genes by a galactosylated polyaspartamide copolymer","volume":"330","author":"Perrone","year":"2021","journal-title":"J.\u00a0Contr. Release"},{"key":"10.1016\/j.mtbio.2022.100350_bib23","article-title":"Overexpression of PD-L1 is an independent predictor for recurrence in HCC patients who receive sorafenib treatment after surgical resection","volume":"11","author":"Tan","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.mtbio.2022.100350_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051089","article-title":"Scientific rationale for combined immunotherapy with PD-1\/PD-L1 antibodies and VEGF inhibitors in advanced hepatocellular carcinoma","volume":"12","author":"Kudo","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.mtbio.2022.100350_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13215295","article-title":"Cure the incurable? Recent breakthroughs in immune checkpoint blockade for hepatocellular carcinoma","volume":"13","author":"Chu","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.mtbio.2022.100350_bib26","article-title":"Clinical trials of immune checkpoint inhibitors in hepatocellular carcinoma","volume":"10","author":"Dyhl-Polk","year":"2021","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.mtbio.2022.100350_bib27","first-page":"20","article-title":"Current treatment options for hepatocellular carcinoma","volume":"33","author":"Eugen","year":"2020","journal-title":"Klin. Onkol."},{"key":"10.1016\/j.mtbio.2022.100350_bib28","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nrclinonc.2016.40","article-title":"Immunotherapy: PD-1 says goodbye, TIM-3 says hello","volume":"13","author":"Romero","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.mtbio.2022.100350_bib29","article-title":"Tim-3 expression and its role in hepatocellular carcinoma","volume":"11","author":"Liu","year":"2018","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.mtbio.2022.100350_bib30","article-title":"The role of TIM-3 in hepatocellular carcinoma: a promising target for immunotherapy?","volume":"10","author":"Hakemi","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.mtbio.2022.100350_bib31","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1038\/s41388-018-0140-4","article-title":"Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-kappaB\/IL-6\/STAT3 axis","volume":"37","author":"Zhang","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.mtbio.2022.100350_bib32","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/hep.25777","article-title":"Tim-3\/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma","volume":"56","author":"Li","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.mtbio.2022.100350_bib33","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1136\/gutjnl-2014-307671","article-title":"Tim-3 fosters HCC development by enhancing TGF-beta-mediated alternative activation of macrophages","volume":"64","author":"Yan","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.mtbio.2022.100350_bib34","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1038\/s41388-018-0140-4","article-title":"Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-kappa B\/IL-6\/STAT3 axis","volume":"37","author":"Zhang","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.mtbio.2022.100350_bib35","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/hep.29513","article-title":"A\u00a0multifunctional nanocarrier for efficient TRAIL-based gene therapy against hepatocellular carcinoma with desmoplasia in mice","volume":"67","author":"Liu","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.mtbio.2022.100350_bib36","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1021\/acs.bioconjchem.5b00254","article-title":"Combination of nanoparticle-delivered siRNA for astrocyte elevated gene-1 (AEG-1) and all-trans retinoic acid (ATRA): an effective therapeutic strategy for hepatocellular carcinoma (HCC)","volume":"26","author":"Rajasekaran","year":"2015","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.mtbio.2022.100350_bib37","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1016\/j.jconrel.2015.05.136","article-title":"Targeting exosomal miRNA with pH-sensitive liposome coated chitosan-siRNA nanoparticles for inhibition of hepatocellular carcinoma metastasis","volume":"213","author":"Wu","year":"2015","journal-title":"J.\u00a0Contr. Release"},{"key":"10.1016\/j.mtbio.2022.100350_bib38","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jconrel.2017.05.017","article-title":"Aptamer-mediated gene therapy enhanced antitumor activity against human hepatocellular carcinoma in vitro and in vivo","volume":"258","author":"Xiao","year":"2017","journal-title":"J.\u00a0Contr. Release"},{"key":"10.1016\/j.mtbio.2022.100350_bib39","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jconrel.2020.11.020","article-title":"Targeted delivery of siRNAs against hepatocellular carcinoma-related genes by a galactosylated polyaspartamide copolymer","volume":"330","author":"Perrone","year":"2021","journal-title":"J.\u00a0Contr. Release"},{"key":"10.1016\/j.mtbio.2022.100350_bib40","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ymthe.2020.10.018","article-title":"Liver injury increases the incidence of HCC following AAV gene therapy in mice","volume":"29","author":"Dalwadi","year":"2021","journal-title":"Mol. Ther. : the journal of the American Society of Gene Therapy"},{"key":"10.1016\/j.mtbio.2022.100350_bib41","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/hep.30337","article-title":"Challenges and opportunities in the clinical development of immune checkpoint inhibitors for hepatocellular carcinoma","volume":"69","author":"Flynn","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.mtbio.2022.100350_bib42","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jconrel.2012.06.027","article-title":"pH-sensitive drug loading\/releasing in amphiphilic copolymer PAE-PEG: integrating molecular dynamics and dissipative particle dynamics simulations","volume":"162","author":"Luo","year":"2012","journal-title":"J.\u00a0Contr. Release"},{"key":"10.1016\/j.mtbio.2022.100350_bib43","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jconrel.2007.07.012","article-title":"Tumoral acidic extracellular pH targeting of pH-responsive MPEG-poly (beta-amino ester) block copolymer micelles for cancer therapy","volume":"123","author":"Ko","year":"2007","journal-title":"J.\u00a0Contr. Release"},{"key":"10.1016\/j.mtbio.2022.100350_bib44","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1166\/jbn.2014.1901","article-title":"PH-sensitive self-assembled carboxymethyl chitosan-modified DNA\/polyethylenimine complexes for efficient gene delivery","volume":"10","author":"Liu","year":"2014","journal-title":"J.\u00a0Biomed. Nanotechnol."},{"key":"10.1016\/j.mtbio.2022.100350_bib45","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1166\/jbn.2016.2206","article-title":"Carboxymethyl chitosan-modified polyamidoamine dendrimer enables progressive drug targeting of tumors via pH-sensitive charge inversion","volume":"12","author":"Qi","year":"2016","journal-title":"J.\u00a0Biomed. Nanotechnol."},{"key":"10.1016\/j.mtbio.2022.100350_bib46","first-page":"6185","article-title":"pH-Sensitive carboxymethyl chitosan-modified cationic liposomes for sorafenib and siRNA co-delivery","volume":"10","author":"Yao","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.mtbio.2022.100350_bib47","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1016\/j.biomaterials.2014.03.012","article-title":"Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles","volume":"35","author":"Feng","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.mtbio.2022.100350_bib48","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1002\/adfm.201600417","article-title":"Enhanced nanodrug delivery to solid tumors based on a tumor vasculature-targeted strategy","volume":"26","author":"Song","year":"2016","journal-title":"Adv. Funct. Mater."}],"container-title":["Materials Today Bio"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S259000642200148X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S259000642200148X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:25:19Z","timestamp":1762907119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S259000642200148X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":48,"alternative-id":["S259000642200148X"],"URL":"https:\/\/doi.org\/10.1016\/j.mtbio.2022.100350","relation":{},"ISSN":["2590-0064"],"issn-type":[{"value":"2590-0064","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved anti-hepatocellular carcinoma effect by enhanced Co-delivery of Tim-3 siRNA and sorafenib via multiple pH triggered drug-eluting nanoparticles","name":"articletitle","label":"Article Title"},{"value":"Materials Today Bio","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mtbio.2022.100350","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100350"}}